Arcutis Biotherapeutics, Inc.
Financials
Valuation Metrics
Arcutis Biotherapeutics, Inc.'s Market Cap is $3.91B. At end of 2025 it was $3.72B. Ranked #1504 of 3,118 in US market (top 48%), #520 of 1,474 on NASDAQ (top 35%), #86 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $3.91B | US#1,504/3,118 Sec#86/265 |
| Revenue | $464M | US#2,264/3,118 Sec#76/265 |
| Net Income | $29M | US#2,027/3,118 Sec#65/265 |
| Total Assets | $489M | US#2,767/3,118 Sec#166/265 |
| Net Assets | $221M | US#2,636/3,118 Sec#178/265 |
| Employees | 354 | US#2,368/3,118 Sec#104/265 |
| Value | ||
| P/E | 137.06x | US#2,145/3,118 Sec#70/265 |
| P/B | 17.72x | US#2,763/3,118 Sec#213/265 |
| P/S | 8.42x | US#2,640/3,118 Sec#108/265 |
| EV/EBITDA | 90.39x | US#2,422/3,118 Sec#78/265 |
| FCF Yield | 1.00% | US#2,166/3,118 Sec#80/265 |
| Profitability | ||
| ROE | 12.93% | US#1,056/3,118 Sec#43/265 |
| ROA | 5.84% | US#933/3,118 Sec#51/265 |
| Op. Margin | 7.38% | US#1,783/3,118 Sec#66/265 |
| Revenue Growth | 76.11% | US#136/3,118 Sec#38/265 |
| Financial Health | ||
| Debt Ratio | 121.48% | US#1,262/3,118 Sec#172/265 |
| Total Debt | $114M | US#2,389/3,118 Sec#112/265 |
| FCF | $39M | US#2,052/3,118 Sec#73/265 |
| Cash | $34M | US#2,712/3,118 Sec#242/265 |
| Current Ratio | 2.92x | US#806/3,118 Sec#193/265 |
| Net Debt/EBITDA | 1.81x | US#1,262/3,118 Sec#53/265 |
| Performance | ||
| 1Y Return | 23.47% | US#907/3,118 Sec#98/265 |
| 1M Return | 24.21% | US#208/3,118 Sec#16/265 |
| From 52W High | -6.16% | US#307/3,118 Sec#26/265 |
| 1Y MDD | -37.50% | US#1,783/3,118 Sec#101/265 |
| Trading | ||
| Volume | 1,196,167 shares | US#1,177/3,118 Sec#110/265 |
| Trading Value | $38M | US#1,333/3,118 Sec#83/265 |
| Per Share | ||
| EPS | $0.23 | US#2,014/3,118 Sec#66/265 |
| BPS | $1.76 | US#2,588/3,118 Sec#182/265 |
Company Info
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.